• HATU for Peptide Synthesis Chemistry

  2026-10-01

  HATU provides a practical route to rapid carboxylic acid activation for challenging amide and ester formation. This guide connects reaction setup, peptide coupling with DIPEA, scale-conscious troubleshooting, and inhibitor-oriented design lessons from a selective IRAP discovery study.

• URB597 (KDS-4103): Selective FAAH Inhibition

  2026-10-01

  URB597, also called KDS-4103, is a potent and selective FAAH inhibitor that elevates anandamide and related fatty-acid ethanolamides. Its defined potency, selectivity profile, and rat pharmacodynamic benchmarks make it useful for endocannabinoid signaling modulation, neuroplasticity research, and neuroinflammation studies.

• VE-822: ATR Inhibitor Workflow for Radiosensitization

  2026-09-30

  VE-822 provides a practical way to test ATR-dependent DNA damage response inhibition across radiation, gemcitabine, and 2D or 3D tumor models. This guide connects potency-led dose finding with reproducible radiosensitization workflows, PDAC applications, and troubleshooting for formulation and assay variability.

• HotStart™ 2X Green qPCR Master Mix in AD

  2026-09-30

  Explore how HotStart™ 2X Green qPCR Master Mix supports mechanistic Alzheimer’s disease research, from BNIP3-linked mitophagy to reproducible real-time transcript quantification. This article presents an assay-design framework that connects SYBR Green chemistry with pathway validation, RNA-seq confirmation, and functional neurobiology.

• Mechanisms of Cell Death in Heart Disease: A Review

  2026-09-29

  This review reframes cardiac cell death as an interconnected network in which apoptosis, regulated necrosis, and autophagy can influence myocardial injury and heart failure. Its principal practical contribution is a mechanistic framework for distinguishing death pathways and designing experiments that combine morphology, bioenergetics, molecular markers, and genetic or pharmacological perturbation.

• BHQ for SERCA Calcium Signaling Research

  2026-09-29

  BHQ enables controlled SERCA inhibition for calcium homeostasis disruption, ER-stress studies, and mechanistic HSC mobilization assays. This practical guide connects calcium imaging, CXCR4 analysis, CFU testing, and vascular physiology while highlighting controls that limit off-target interpretation.

• Cefotaxime BA1012 for Reliable AMR Assays

  2026-09-28

  Learn how Cefotaxime (SKU BA1012) can reduce interpretive ambiguity in bacterial infection models, antimicrobial resistance research, and cell-based viability workflows. This scenario-driven guide connects product handling, assay controls, resistance epidemiology, and practical vendor selection.

• Gemcitabine HCl in MRI-Guided Pancreatic Studies

  2026-09-28

  Pair Gemcitabine HCl’s measurable DNA replication inhibition with longitudinal MRI to connect cell-based potency to tumor response in pancreatic cancer models. A multianimal MRI workflow can image up to four mice in one acquisition session, improving study throughput while preserving individual tumor measurements.

• Aligned Silk Fibroin–Ce6 Films for Infected Wounds

  2026-09-27

  This study combines aligned silk fibroin fibers with conjugated Chlorin e6 (Ce6) to create a wound scaffold that guides cell growth and enables near-infrared photodynamic antibacterial treatment. In the reported experiments, the film generated reactive oxygen species, reduced Staphylococcus aureus infection, and was associated with later-stage M2 macrophage polarization during wound healing.

• Nimbolide, RNF114, and PARP1 Trapping in BRCA Cancer

  2026-09-26

  Li and colleagues identify RNF114 as a PARylation-dependent E3 ubiquitin ligase that helps remove PARP1 from DNA lesions, and show that nimbolide can disrupt this process to promote PARP1 trapping. The preclinical findings connect this pathway to synthetic lethality in BRCA-mutated cancer and suggest a possible way to address resistance to PARP inhibitors, while leaving important questions about selectivity and clinical translation open.

• iPSC Prescreening for Ultrarare Disease Trials

  2026-09-25

  Sequiera and colleagues developed a patient-specific iPSC platform to assess candidate drugs for an ultrarare Leigh-like syndrome associated with ECHS1 variants, addressing the uncertainty of choosing treatments from evidence about genetically different patients. The study reports that three screened drugs were subsequently investigated in the patient and that treatment over three years shifted the metabolic profile toward that of healthy controls, while emphasizing that iPSC results are a prescreening aid rather than proof of clinical benefit.

• Gemcitabine HCl: From DNA Synthesis to Tumor Response

  2026-09-25

  Gemcitabine HCl offers a clear mechanistic starting point for pancreatic cancer studies: DNA synthesis inhibition can be measured in cultured cells, then tested against tumor growth over time. This article connects those scales using KPC models, multianimal MRI, practical protocol considerations, and a translational framework for interpreting treatment response.

• Protease Inhibitor Cocktail: Preserve Protein State

  2026-09-24

  Explore how a Protease Inhibitor Cocktail supports protein-state fidelity in plant extracts—and why preventing extraction damage matters when interpreting regulated protein modifications. A mechanistic study of itaconic acid and TBK1 offers a distinct framework for separating biological change from sample-handling artifacts.

• Nebivolol Hydrochloride: Reading a Negative TOR Screen

  2026-09-24

  Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist, but a 2025 drug-sensitized yeast study found no evidence that it inhibited TOR in that model. This article explains what that negative result means for assay selection, interpretation, and cardiovascular pharmacology research.

• VE-822: From ATR Biology to Better Model Decisions

  2026-09-23

  VE-822 is a potent ATR inhibitor for studying replication-stress signaling and cancer treatment sensitization. This article connects its mechanism to a less-explored question: how model choice and patient-specific screening should shape the interpretation of preclinical results.

8070 records 1/538 page Next 12345 下5页 Last page